相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Recent Advances in the Treatment of Melanoma
Brendan D. Curti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Interleukins in cancer: from biology to therapy
Dania Briukhovetska et al.
NATURE REVIEWS CANCER (2021)
Systemic immunity in cancer
Kamir J. Hiam-Galvez et al.
NATURE REVIEWS CANCER (2021)
IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells
J. M. R. Van der Meer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
Jared E. Lopes et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design
Nikhil Khushalani et al.
FUTURE ONCOLOGY (2020)
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
Ting Zhou et al.
NATURE (2020)
An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
Dilara Sahin et al.
NATURE COMMUNICATIONS (2020)
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
Linh T. Nguyen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel et al.
CANCER DISCOVERY (2019)
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma
Xin Xu et al.
CLINICAL CANCER RESEARCH (2019)
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
Aung Naing et al.
LANCET ONCOLOGY (2019)
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel-Adriano Silva et al.
NATURE (2019)
Phase (Ph) I/Ib study of NIZ985 with and without spartalizumab (PDR001) in patients (pts) with metastatic/unresectable solid tumors
Kevin Conlon et al.
CANCER RESEARCH (2019)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
Li Tang et al.
NATURE BIOTECHNOLOGY (2018)
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects
Yuki Kagoya et al.
NATURE MEDICINE (2018)
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky et al.
SCIENCE (2018)
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
Aung Naing et al.
CANCER CELL (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Kim Margolin et al.
CLINICAL CANCER RESEARCH (2018)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller et al.
CLINICAL CANCER RESEARCH (2018)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Biliang Hu et al.
CELL REPORTS (2017)
The immunomodulatory, antitumor and antimetastatic responses of melanoma-bearing normal and alcoholic mice to sunitinib and ALT-803: a combinatorial treatment approach
Kari A. Gaither et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Zhifeng Ma et al.
CLINICAL CANCER RESEARCH (2016)
NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
Deborah H. Charych et al.
CLINICAL CANCER RESEARCH (2016)
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
Lenka V. Hurton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
Natalia Arenas-Ramirez et al.
Science Translational Medicine (2016)
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Wei Liao et al.
IMMUNITY (2013)
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner
Rebecca Berlant Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cytokine-induced cytokine production by conventional and innate lymphoid cells
Liying Guo et al.
TRENDS IN IMMUNOLOGY (2012)
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
John B. Mumm et al.
CANCER CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A Phase 2, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma
Ahmad A. Tarhini et al.
CANCER (2009)
Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance
H Kobayashi et al.
BLOOD (2005)
Interleukin-10 therapy - Review of a new approach
K Asadullah et al.
PHARMACOLOGICAL REVIEWS (2003)
IL-15Rα recycles and presents IL-15 in trans to neighboring cells
S Dubois et al.
IMMUNITY (2002)
分享论文
